Adriana Juárez
About Adriana Juárez
Adriana Juárez is a tax manager with over 17 years of experience, currently working at Thales and Bristol-Myers Squibb.
Current Position at Thales and Bristol-Myers Squibb
Adriana Juárez holds the position of Gerente De Impuestos at Thales and Bristol-Myers Squibb. She manages tax-related responsibilities at both multinational companies, demonstrating her expertise in tax management and multinational corporate tax regulations.
Previous Roles in Tax Management
Adriana Juárez's career includes significant roles in tax management at various prestigious organizations. From 2013 to 2014, she was an Especialista de Impuestos at Sanofi. She also served as Gerente de Impuestos at Laboratorios Sanfer from 2006 to 2013, and as Asesor Fiscal at Escobar Latapí Consultores, S.C. from 2004 to 2006. These roles have equipped her with extensive experience in both tax consultancy and management.
Educational Background
Adriana Juárez holds multiple degrees. She studied at the Facultad de Derecho de la Barra Nacional de Abogados from 2015 to 2018. Additionally, she has two separate academic periods at Universidad Nacional Autónoma de México, from 2008 to 2011 and from 2000 to 2004. She has also pursued studies at IEU Universidad. Her robust educational background has laid a strong foundation for her career in tax management.
Experience in International Tax Regulations
Throughout her career, Adriana Juárez has held managerial positions in multinational companies, which has provided her with in-depth knowledge of international tax regulations. Her ability to navigate complex tax environments across different countries has been demonstrated in her roles at Thales, Bristol-Myers Squibb, Sanofi, and Laboratorios Sanfer.
Expertise in Pharmaceutical Industry Tax Management
Adriana Juárez's prolonged tenure at Laboratorios Sanfer, where she worked as Gerente de Impuestos for seven years, highlights her expertise in the pharmaceutical industry's tax management. Her experience in this sector underscores her capability to handle the unique tax challenges faced by pharmaceutical companies.